The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409980

Authors

Farshad Sheybaee Moghaddam

Sami Dwabe

Nataliya Mar

Leila Safdari

Navin Sabharwal

Hanan Goldberg

Michael Daneshvar

Arash Rezazadeh Kalebasty

Affiliations

Soon will be listed here.

Abstract

Radical cystectomy with lymph node dissection and urinary diversion is the gold-standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC). However, in patients who refuse cystectomy, or in whom cystectomy carries a high risk, bladder-preserving therapies remain potential options. Bladder preservation therapies can include maximal debulking transurethral resection of bladder tumor (TURBT), concurrent chemoradiation therapy, followed by cystoscopy to assess response. At this time, maximal TURBT is recommended for patients prior to the initiation of chemoradiation therapy or in patients with residual bladder tumors after the completion of chemoradiation therapy. That being said, TURBT carries significant risks such as bladder perforation, bleeding, and infection, ultimately risking delayed systemic treatment. Hence, understanding its role within trimodal therapy is crucial to avoid undue suffering in patients. Herein, we review the current literature on the impact of debulking TURBT in non-metastatic MIBC.

References

Zamboni S, Moschini M, Gallina A, Colombo R, Montorsi F, Briganti A . The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. World J Urol. 2019; 37(12):2707-2714. DOI: 10.1007/s00345-019-02734-6. View

Klempfner H, Anderson P . Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review. BJUI Compass. 2024; 5(7):651-661. PMC: 11250143. DOI: 10.1002/bco2.365. View

van Rhijn B, Burger M, Lotan Y, Solsona E, Stief C, Sylvester R . Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56(3):430-42. DOI: 10.1016/j.eururo.2009.06.028. View

Ferro M, Barone B, Crocetto F, Lucarelli G, Busetto G, Del Giudice F . Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urol Oncol. 2022; 40(11):490.e13-490.e20. DOI: 10.1016/j.urolonc.2022.05.016. View

Eswara J, Efstathiou J, Heney N, Paly J, Kaufman D, McDougal W . Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2011; 187(2):463-8. DOI: 10.1016/j.juro.2011.09.159. View

Panebianco V, Briganti A, Boellaard T, Catto J, Comperat E, Efstathiou J . Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System. Nat Rev Urol. 2023; 21(4):243-251. DOI: 10.1038/s41585-023-00830-2. View

Ghandour R, Kusin S, Wong D, Meng X, Singla N, Freifeld Y . Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. Urol Oncol. 2020; 38(9):736.e11-736.e18. DOI: 10.1016/j.urolonc.2020.05.032. View

Rodel C, Grabenbauer G, Kuhn R, Papadopoulos T, Dunst J, Meyer M . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14):3061-71. DOI: 10.1200/JCO.2002.11.027. View

Kukreja J, Porten S, Golla V, Ho P, Noguera-Gonzalez G, Navai N . Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2017; 4(5):720-724. DOI: 10.1016/j.euf.2016.12.005. View

10.

Mariappan P, Finney S, Head E, Somani B, Zachou A, Smith G . Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation.... BJU Int. 2011; 109(11):1666-73. DOI: 10.1111/j.1464-410X.2011.10571.x. View

11.

Holzbeierlein J, Bixler B, Buckley D, Chang S, Holmes R, James A . Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024; 212(1):3-10. DOI: 10.1097/JU.0000000000003981. View

12.

Huang J, Fu J, Zhan H, Xie K, Liu B, Yang F . Analysis of the absence of the detrusor muscle in initial transurethral resected specimens and the presence of residual tumor tissue. Urol Int. 2012; 89(3):319-25. DOI: 10.1159/000341103. View

13.

Luo C, Huang B, Wu Y, Chen J, Chen L . Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur Radiol. 2020; 30(8):4606-4614. DOI: 10.1007/s00330-020-06802-z. View

14.

Mak K, Smith A, Eidelman A, Clayman R, Niemierko A, Cheng J . Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016; 96(5):1028-1036. DOI: 10.1016/j.ijrobp.2016.08.023. View

15.

Ferro M, Chiujdea S, Musi G, Lucarelli G, Del Giudice F, Hurle R . Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clin Genitourin Cancer. 2022; 20(2):e166-e172. DOI: 10.1016/j.clgc.2021.12.005. View

16.

Efstathiou J, Spiegel D, Shipley W, Heney N, Kaufman D, Niemierko A . Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2011; 61(4):705-11. DOI: 10.1016/j.eururo.2011.11.010. View

17.

Zlotta A, Ballas L, Niemierko A, Lajkosz K, Kuk C, Miranda G . Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023; 24(6):669-681. DOI: 10.1016/S1470-2045(23)00170-5. View

18.

Bryan R, Liu W, Pirrie S, Amir R, Gallagher J, Hughes A . Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol. 2021; 80(1):12-15. DOI: 10.1016/j.eururo.2021.02.021. View

19.

de Ruiter B, van Hattum J, Lipman D, de Reijke T, Jeroen A van Moorselaar R, van Gennep E . Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. Eur Urol. 2022; 82(5):518-526. DOI: 10.1016/j.eururo.2022.07.009. View

20.

Roupret M, Yates D, Varinot J, Phe V, Chartier-Kastler E, Bitker M . The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Can J Urol. 2012; 19(5):6459-64. View